Teewinot Technologies

Teewinot Life Sciences is a biotechnology company specializing in the biosynthetic production of cannabinoids. The company utilizes a proprietary biocatalytic platform to manufacture pharmaceutical-grade cannabinoids, including rare variants like CBG, CBC, and THCV, which are difficult to extract from plants in high purity. Their technology bypasses traditional cultivation and extraction, offering a more scalable and cost-effective solution for drug development. In 2020, the company's assets were acquired by Cronos Group to enhance their cannabinoid research and production capabilities. The company's intellectual property portfolio covers the production of over 18 different cannabinoids using enzymatic processes.